Genelux (GNLX) Free Cash Flow (2022 - 2026)
Genelux (GNLX) posted quarterly Free Cash Flow of -$7.0 million for Q1 2026, down 27.72% year-over-year from -$9.7 million in Q1 2025, and down 5.2% quarter-over-quarter from -$6.6 million in Q4 2025.
Genelux (GNLX) Free Cash Flow (2022 - 2026) Analysis & Trends
Genelux's Free Cash Flow history runs 5 years deep, the most recent figure standing at -$7.0 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 27.72% year-over-year to -$7.0 million; the TTM figure through Mar 2026 stood at -$27.9 million (down 22.88% YoY), while the FY2025 annual figure was -$26.4 million, down 22.01% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$7.0 million, down from -$6.6 million in the prior quarter.
- The five-year high for Free Cash Flow was $2.8 million in Q1 2022, with the low at -$7.2 million in Q2 2025.
- The 5-year median for Free Cash Flow is -$5.8 million (2024), against an average of -$5.0 million.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow tumbled 371.21% in 2023, then jumped 38.52% in 2024.
- Genelux's Free Cash Flow stood at -$1.5 million in 2022, then sank by 371.21% to -$7.2 million in 2023, then surged by 38.52% to -$4.4 million in 2024, then sank by 50.86% to -$6.6 million in 2025, then fell by 5.2% to -$7.0 million in 2026.
- Business Quant data shows GNLX's Free Cash Flow at -$7.0 million in Q1 2026, -$6.6 million in Q4 2025, and -$7.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | -7.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.98 Mn |
| Mar 31, 2026 | -6.98 Mn |
| Dec 31, 2025 | -6.64 Mn |
| Dec 31, 2025 | -6.64 Mn |
| Sep 30, 2025 | -7.09 Mn |
| Sep 30, 2025 | -7.09 Mn |
| Jun 30, 2025 | -7.18 Mn |
| Jun 30, 2025 | -7.18 Mn |
| Mar 31, 2025 | -5.47 Mn |
| Mar 31, 2025 | -5.47 Mn |
| Dec 31, 2024 | -4.40 Mn |
| Dec 31, 2024 | -4.40 Mn |
| Sep 30, 2024 | -5.78 Mn |
| Sep 30, 2024 | -5.78 Mn |
| Jun 30, 2024 | -7.05 Mn |
| Jun 30, 2024 | -7.05 Mn |
| Mar 31, 2024 | -4.38 Mn |
| Mar 31, 2024 | -4.38 Mn |
| Dec 31, 2023 | -7.15 Mn |
| Dec 31, 2023 | -7.15 Mn |